Generic Substitution of Original Levetiracetam in Thai Epilepsy Patients
Generic Substitution of Original Levetiracetam in Thai Epilepsy Patients
The retrospective pre-post observational study was conducted to evaluate the real-world
 evidence of efficacy and tolerability of generic levetiracetam (oral tablet) which was
 switched from original levetiracetam (oral tablet) in patients with epilepsy at the national
 hospital for neurology and neurosurgery in Thailand. Epilepsy patients who received generic
 substitution to original levetiracetam at the same dose and had stable conditions of seizure
 were only included. In the period of 6 months, the investigators assessed the change of
 seizure frequency, the incidence of hospitalization due to breakthrough seizure, the
 incidence of adverse events and the incidence of composite outcomes related to dosage
 adjustment of antiepileptic drugs.
Inclusion Criteria:

 -  Diagnosis of epilepsy for at least 6 months prior to generic levetiracetam
 substitution;

 -  Same dosage form and strength of generic substitution to original levetiracetam;

 -  Stable dose of original levetiracetam and stable seizure frequency prior to generic
 levetiracetam substitution;

 -  Stable dose of generic levetiracetam after generic levetiracetam substitution

 Exclusion Criteria:

 -  Absence seizure with levetiracetam monotherapy;

 -  Original levetiracetam in dosage form of oral solution or intravenous solution prior
 to generic levetiracetam substitution;

 -  Poor compliance;

 -  Death or loss of follow up;

 -  Unavailable data for evaluation of outcomes